Brief: Paratek Pharma Reports Publication Of Data From Study Of Nuzyra
08/03/2022 23:06
March 8 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES THE PUBLICATION OF DATA
FROM
AN INVESTIGATOR-INITIATED STUDY OF NUZYRA® (OMADACYCLINE) IN A
HOLLOW FIBER SYSTEM MODEL AGAINST PULMONARY MYCOBACTERIUM AVIUM
COMPLEX
Source text for Eikon: ID:nGNX9NtJhL
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million